Company intelligence / Profile preview

DEMECAN

Berlin, Berlin, Germanydemecan.de ↗
Ownership
Private
Employees
~100
Development stage
Other
01

Overview

DEMECAN is a leading German pharmaceutical company specializing in the entire value chain of medical cannabis, from cultivation and processing to distribution. As one of the few entities licensed by the Federal Institute for Drugs and Medical Devices (BfArM) to produce medical cannabis in Germany, the company operates a state-of-the-art GMP-certified manufacturing facility in Saxony. Their product portfolio includes high-quality cannabis flowers, full-spectrum extracts, and Dronabinol, aimed at treating chronic pain and other complex conditions. DEMECAN focuses on ensuring a reliable supply of medical-grade cannabinoids to pharmacies and wholesalers across the European market. The company is vertically integrated, combining pharmaceutical expertise with advanced indoor cultivation technology to meet strict regulatory standards.

Therapeutic areas
GastroenterologyPsychiatryNeurology
Modalities
Small moleculeBotanical extractPlant extract
Industry
Pharma
02

Drug pipeline

28 assets

CRAFT Cali 29:01

3

27 more assets in the full pipeline.

03

Partnerships

BfArM (Federal Institute for Drugs and Medical Devices)

Beyond the preview

Go deeper on DEMECAN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DEMECAN.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call